INTRODUCTION

Traumatic brain injury (TBI) is a global health problem and a major cause of long-term disability and death among all trauma-related injuries. An estimated 5.3 million Americans live with a disability due to TBI (from the report to congress, traumatic brain in the United States, Centers for Disease Control and Prevention; www.cdc.gov/traumaticbraininjury/pubs/tbi_report_to_congress.html). The direct and indirect cost of TBI was around $48.3 billion annually in the United States and €33 billion in Europe for 2010. Up to now, there is no effective pharmacological therapy for TBI in patients. It is critical to develop new treatments for TBI.
TBI induces primary injury directly from the traumatic impact, followed by a secondary injury from the response to the impact. Infammation is a major cause of secondary injury. TBI upregulates the expression of cytokines and chemokines, activates microglia, and migrates peripheral immune cells to the lesioned brain. In mice receiving moderate TBI, the levels of IL-1β, tumor necrosis factor-alpha, and IL-6 peaked at 3-9 hours post-injury in the cortex. Similarly, the expression of IL-6, IL-8, IL-10, and TNF-alpha peaked in 2 days after moderate-severe TBI in patients. These inflammatory responses lead to apoptosis, gliosis, and neurodegeneration. It is thus likely that the secondary injury of TBI can be modulated by anti-inflammation-based therapy.

Mu opioid receptor (MOR) antagonists have been used to treat drug dependence in patients. Selective MOR antagonists were found to possess neuroprotective or anti-inflammatory activity. For example, naltrexone (brand names include ReVia and Vivitrol), a medication primarily used to manage alcohol or opioid dependence, reduced the expression of proapoptotic proteins BAD and BAX in the mouse cell culture. A meta-analysis indicated that early treatment with naloxone reduced mortality and improved prognosis in patients with severe TBI. Interestingly, the protective action of MOR antagonists was also found in their (+) stereoisomers, which does not interact with MOR. Intranasal delivery of (+) naloxone reduced microglia activation and promoted behavioral recovery in stroke rats. (+) Naloxone was equally effective as (−) naloxone in inhibiting LPS-mediated microglia activation in culture. These data suggest that naloxone may reduce neuroinflammation through non-MOR mechanisms.

The purpose of this study was to characterize the neuroprotective action of naltrexone in a controlled cortical impact (CCI) model of TBI. MOR knockout (KO) and wild-type (WT) mice were used to identify the specific action of the MORs. The KO mice had no detectable MOR. The binding and function of delta or kappa opioid receptors in the KO mice were not affected. We demonstrated that naltrexone suppressed TBI-mediated bradykinesia and altered microglia activation in both KO and WT mice. Naltrexone differentially inhibited TBI-mediated CD4 expression in KO and WT. Our data suggest that naltrexone reduced inflammation and neurodegeneration through non-MOR and MOR-mediated mechanisms.

2 | MATERIALS AND METHODS

2.1 | Animals

MOR KO and WT mice were kindly provided by Dr. Horace H Loh. The animals were bred at the National Health Research Institutes (NHRI). The use of animals was approved by the Animal Research Committee of the NHRI (approved number: 109097A, 108146A). All animal experiments were carried out in accordance with the National Institutes of Health guide for the care and use of Laboratory Animals (NIH Publications No. 8023, revised 1978). All mice were kept in an animal room with a 12-h light/dark cycle at a temperature of 25 ± 2°C and humidity of 55%. A standard diet and water were provided ad libitum.

2.2 | Primary mouse cortical neurons and BV2 microglia co-cultures

Primary cortical neurons (PCNs) and BV2 microglia co-cultures were prepared, as we previously described. Cerebral cortical cells were obtained from E14-15 fetuses of timed pregnant WT or KO mice. After removing the blood vessels and meninges, pooled cortices were trypsinized (0.05%; Invitrogen, Carlsbad, CA) for 20 min at room temperature. After rinsing with pre-warmed Dulbecco's modified Eagle's medium (Invitrogen), cells were dissociated by titration, counted, and plated into 96-well (5.0 × 10^4/well) cell culture plates precoated with poly-D-lysine (Sigma-Aldrich, St. Louis, MO, USA). The cultures were maintained at 37°C in a humidified atmosphere of 5% CO_2 and 95% air. The cultures were fed by exchanging 50% of media with feeding media (Neurobasal Medium, Invitrogen) with 0.5 mM L-glutamine (Sigma-Aldrich, St. Louis, MO, USA), 0.025 mM L-glutamate (Sigma-Aldrich, St. Louis, MO, USA), and 2% B27 (Invitrogen, Carlsbad, CA). Cultures were maintained at 37°C in a humidified atmosphere of 5% CO_2 and 95% air. The cultures were fed by exchanging 50% of media with feeding media (Neurobasal Medium, Invitrogen) with 0.5 mM L-glutamine and 2% B27 with an antioxidant supplement on days in vitro (DIV) 3 and 5. BV2 microglia were cultured separately, detached by 0.05% trypsin-ethylenediaminetetraacetic acid (EDTA, Invitrogen, Carlsbad, CA), and centrifuged at 100 g for 5 min. BV2 cells were resuspended in the feeding media containing B27 supplement without antioxidants (AAO, from Invitrogen). The density of surviving cells was counted using a trypan blue assay; cells were plated on the PCN-plated wells at a concentration of 3.0x10^3/well on DIV 7. On DIV 10, cultures were treated glutamate with naltrexone or vehicle. At 48 hr after drug treatment, cells were fixed 4% paraformaldehyde (PFA, Sigma-Aldrich, St. Louis, MO, USA) for 1 hr at room temperature.

2.3 | Immunocytochemistry

Cultured cells were fixed with PFA for 1 hr, washed with PBS, and incubated with a mouse monoclonal antibody against MAP2 (1:500) or a rabbit polyclonal antibody against IBA1 (1:500) for 1 day at 4°C. The bound primary antibodies were later interacted with secondary antibodies (Alexa Fluor 488 goat anti-mouse or Alexa Fluor 568 goat anti-rabbit antibody, Invitrogen). Images were acquired by a DS-Qi2 camera (Nikon, Melville, NY) attached to a NIKON ECLIPSE Ti2 (Nikon, Melville, NY). Data were analyzed using NIS Elements AR 5.11 Software (Nikon).
2.4 Controlled cortical impact (CCI) and naltrexone injection

Adult male MOR WT and KO mice are anesthetized with isoflurane and placed in a stereotaxic frame. A midline incision was made to expose the skull, and a 4 mm craniotomy was made centered at −2 mm posterior to bregma and 0.5 mm lateral to midline over the left hemisphere. Mice were subjected to CCI at a 1.0 mm impact depth and a nominal velocity of 5 m/s. The dwell time was 500 ms, and the tip size was 2 mm. A computer-controlled pneumatically driven piston from the CCI impactor device (TBI-0310 Impactor, Precision Systems and Instrumentation, Fairfax Station, VA) was used to impact the brain. After the impact, the head wound was sutured. Body temperature was maintained at 37°C using a temperature-controlled incubator. Control animals received sham surgery, including craniotomy without cortical impact. Naltrexone (Sigma, Cat. No: N3136, 10 mg/kg/d) or vehicle was given subcutaneously from day 2 to day 5 after CCI.

2.5 Behavioral test

Locomotor activity was examined on day 5 after CCI. Mice were individually placed in 42 × 42 × 26 cm Plexiglas activity chambers containing horizontal and vertical infrared sensors (Accuscan, Columbus, OH) placed 2.5 cm apart. Two variables were measured: (i) horizontal activity (HACTV, the total number of beam interruptions that occurred in the horizontal sensors in one hour) and (ii) vertical activity (VACTV, the total number of beam interruptions that occurred in the vertical sensor in one hour).

2.6 Immunohistochemistry

Brains were removed and dissected, post-fixed in 4% paraformaldehyde (PFA) for 48 hr, and transferred to 20% sucrose in 0.1 M phosphate buffer (PB) for at least 16 h. Serial sections of the entire brain were cut at 25 μm thickness on a freezing cryostat (Leica Model: CM 3050 S). After blocking with 4% bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA) and 0.3% Triton X-100 in 0.1 M PB, sections were incubated with antibodies against ionized calcium-binding adapter molecule 1 (polyclonal, IBA1; 1:100; Abcam, Cambridge, MA, USA) and kept at 4°C overnight. Control sections were incubated without the primary antibody. Sections were washed three times with 0.1 M PB and incubated in Alexa Fluor 488 goat anti-mouse IgG (1:500, Thermo Fisher Scientific, Waltham, MA, USA) for 60 min at room temperature. Sections were mounted on slides and coverslipped. Confocal analysis was performed using a Nikon D-ECLIPSE 80i microscope (Nikon Instruments, Inc., Tokyo, Japan) and the EZ-C1 3.90 software (Nikon, Tokyo, Japan). The optical density of IBA1 immunoreactivity was quantified in three consecutive brain sections with a visualized anterior commissure in each animal, as previously reported. Two photomicrographs were taken along the perilesion region per brain slice.

2.7 Western blotting

The right and left cerebral cortices were collected. Tissue was homogenized in RIPA lysis buffer (Merk Millipore, MA, USA) and then was centrifuged at 13 200 rpm for 10 min at 4°C. The supernatant was collected. A bicinchoninic acid (BCA) protein assay was performed to determine protein concentrations. The samples were diluted with RIPA buffer according to the BCA protein assay. Gels were transferred to a PVDF membrane (PerkinElmer, Waltham, MA) after electrophoresis. The membranes were blocked in 5% milk at room temp for 1 hr. The blots were then probed with primary antibodies against ionized calcium-binding adapter molecule 1 (polyclonal, IBA1; 1: 500, Wako, Osaka, Japan), inducible nitric oxide synthase (monoclonal, iNOS, 1:1000, BD, San Jose, CA), CD4 (polyclonal, 1:500, Proteintech, IL, USA), or actin (monoclonal, 1: 10,000, Novus, CO, USA) at 4°C for overnight. The membrane was then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (Jackson laboratory) at room temp for 1 hr, followed by washing with 0.1% Tween-20 (in PBS) three times for 10 min each. The light emission signal of the target proteins on the PVDF membrane was generated by using a Western Lightning Plus-ECL (PerkinElmer, MA, USA) and then detected by X-ray film (Cat. No. GE28-9068-39, GE, Boston, USA). The amount of IBA1 and iNOS was normalized with actin on the same membrane. Band intensity was quantified using ImageJ.

2.8 Quantitative reverse transcription polymerase chain reaction (qRT-PCR)

Cerebral cortical tissues were collected for qRT-PCR analysis. Total RNAs were isolated using TRIzol Reagent (Thermo Fisher,

| TABLE 1 Oligonucleotide primers used for qRT-PCR |
|-----------------------------------------------|
| Gene | SYBR Green Forward | SYBR Green Reverse | TaqMan universal probe Library # |
|------|---------------------|--------------------|---------------------------------|
| GDNF | TAAGATGAAGTTATGGGATGTCG | CTTCTAGAAAGGCTCTTACC | Roche 112 |
| MOR  | ACTGGGAGAAACCTGCTCAA | GGGGCACAGCACAGCAATAA | Mm02619580_g1 |
| β-Actin | Mm99999915_00 | |
| GAPDH | Mm99999915_15 | |
#15596-018, MA, USA), and cDNAs were synthesized from 1 µg total RNA using RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Scientific, #K1631). MOR and GDNF mRNA expression was measured by using SYBR Green (Luminaris Color HiGreen Low ROX qPCR Master Mix; Thermo Scientific, MA, USA) or TaqMan Fast (Life Technologies). Quantitative real-time PCR (qRT-PCR) was carried out using TaqMan Fast Advanced Master Mix (Life Technologies, #4444557) and QuantStudio™ 3 Real-Time PCR System (Thermo Scientific). The expression of target genes was normalized to the reference genes (beta-actin and GAPDH average) with a modified delta-delta-Ct algorithm. All experiments were duplicated. The primers for GDNF, MOR, beta-actin, and GAPDH are listed in Table 1.

2.9 | Statistical analysis

Data were presented as mean ±SEM. The normality of variables was examined by the Shapiro-Wilk test. Data that did not exhibit a normal distribution were analyzed via a non-parametric equivalent. One- or two-way ANOVA and post hoc Newman-Keuls tests (NK test) were used for statistical comparisons, with a significance level of \( P < 0.05 \).

3 | RESULTS

3.1 | Naltrexone induced neuroprotection in neuron/microglia co-culture

Primary cortical neurons (PCNs) from WT mouse embryos were co-cultured with BV2 microglial as previously described.\textsuperscript{24} Glutamate (Glu)-mediated neuronal loss was examined by MAP-2 immunostaining. Glu (15 µM, \( n = 6 \)) significantly reduced MAP2-ir (Figure 1B vs 1A; Figure 1J, \( P < 0.001 \)); this response was antagonized by naltrexone (10 µM; Figure 1C and J, \( P < 0.001 \), \( F_{2, 15} = 39.022 \), one-way ANOVA+NK test). Glu enhanced IBA1-ir (Figure 1E vs 1D; Figure 1K, \( P = 0.004 \)), which was also antagonized by naltrexone.
We next examined whether knocking out MOR receptors altered the protective action of naltrexone. PCNs from MOR KO embryos were co-cultured with BV2 microglia. Glu (15 µM, n = 6) significantly reduced MAP2-ir (Figure 2B, $P < 0.001$) and enhanced IBA1-ir (Figure 2E, $P < 0.001$); both responses were significantly antagonized by naltrexone (MAP2: Figure 2C and J, $P < 0.001$, $F_{2,15} = 28.578$; IBA1: Figure 2F and K, $P < 0.001$, $F_{2,15} = 50.818$, one-way ANOVA +NK test).

### 3.2 Naltrexone improved locomotor activity in KO and WT mice

A total of 31 WT and 28 MOR KO mice received CCI or sham surgery on day 0 and were treated with vehicle (WT: n = 15; MOR KO n = 14) or naltrexone (WT: n = 16; MOR KO n = 14. 10 mg/kg/d, s.c.) from days 2 to 5. Locomotor activity was examined on day 5. TBI significantly reduced horizontal activity (HACTV) and vertical activity (VACTV) in the WT and KO mice. (Figure 3, Table 2). No difference was found between WT and KO (Table 2, two-way ANOVA). Treatment with naltrexone normalized HACTV and VACTV in the lesioned WT and KO mice (Figure 3, Table 2).

### 3.3 Naltrexone reduced TBI-mediated microglial activation in WT and KO mice

A total of 22 mice were used for IBA1 immunostaining. Of these, 11 mice (5 WT +6 KO) received TBI, followed by vehicle injection. The other 11 mice (5 WT +6 KO) received naltrexone after TBI. Brain tissues were collected on day 5. Enhanced IBA1-ir and deramified microglial morphology were found in the perilesioned area of WT (Figure 4 A2) and KO (Figure 4 B2) mice receiving vehicle. Resting microglia exhibiting ramified morphology were found in the contralateral (non-lesioned side) cortex (Figure 4 A1 and B1). TBI-enhanced IBA1 immunoreactivity and microglia activation were antagonized by naltrexone.
naltrexone in the WT and KO mice (WT: Figure 4 A3 and KO: Figure 4 B3). The optical density of IBA1 immunofluorescence in the perilesion zone was quantified and averaged from 5 images taken from the brain slices with visible anterior commissures. IBA1-ir was significantly enhanced in the lesioned brain. No difference was found between the WT and KO (P = 0.219). Naltrexone significantly reduced IBA1 optical density in WT (P < 0.001, two-way ANOVA+NK test) and KO mice (Figure 4C, P < 0.001).

3.4 | TBI increased IBA1, iNOS, and CD4 protein levels in WTs and KOs

The lesioned and non-lesioned side cortices were collected from 12 WT and 12 KO mice on day 5 post-TBI for Western analysis (Figure 5). TBI significantly increased IBA1 (Figure 6 A1, P < 0.001, WT; Figure 6 A2, P < 0.001, KO, two-way ANOVA+NK test), iNOS (Figure 6 B1, P = 0.003, WT; Figure 6 B2, P < 0.001, KO), and CD4 protein levels (Figure 6 C1, P = 0.015, WT; Figure 6 C2, P = 0.001, KO) in the lesioned brains. Naltrexone significantly mitigated TBI-induced IBA1 (WT: Figure 6 A1, P = 0.002; KO: Figure 6 A2, P < 0.001) and iNOS (WT: Figure 6 B1, P < 0.001; KO: Figure 6 B2 P = 0.025). No difference was found between KO and WT mice (IBA1: P = 0.258, Figure 6 A1 vs A2; iNOS, P = 0.197, Figure 6 B1 vs B2, two-way ANOVA+NK test). Naltrexone selectively antagonized TBI-mediated CD4 expression in the WTs (P = 0.005, Figure 6 C1), but not in the KOs (P = 0.815, Figure 6 C2).

3.5 | Naltrexone did not alter the expression of MOR and GDNF

Brain tissues from 12 WT and 14 KO mice were collected on day 5 for qRT-PCR analysis. As expected, no detectable MOR mRNA was found in the KO mice (P < 0.001, WT vs KO). TBI or naltrexone treatment did not alter the MOR expression in WT mice (Figure 7 A1. TBI vs non-TBI: P = 0.635; naltrexone vs vehicle: P > 0.05, two-way ANOVA). TBI significantly increased GDNF expression in WT (Figure 7 B1, P = 0.002) and KO (Figure 7 B2, P < 0.001). Naltrexone did not alter expression of GDNF (WTs: Figure 7 B1, P = 0.416; KOs: Figure 7 B2: P = 0.168).

4 | DISCUSSION

Naltrexone-induced neuroprotection was examined in neuron/microglia co-culture and a mouse model of TBI. We demonstrated...
that naltrexone significantly reduced glutamate-mediated neuronal loss and microglia activation in the co-culture. In both MOR WT and KO mice, early post-treatment of naltrexone improved locomotor activity, while reduced microglia activation and iNOS expression after TBI. Naltrexone selectively inhibited TBI-mediated CD4 expression in WT mice. The main finding in this study is that naltrexone induced protection in the TBI brain through anti-inflammation.

Several studies have supported that MOR agonists modulate neuroinflammation after brain injury. For example, morphine increased NF-κB levels in LPS-activated microglia. This response is selective to MOR as NF-κB was also activated by MOR agonist
DAMGO, but not with delta or kappa opioid agonists DPDPE or U69593. Furthermore, transfection with siRNAs that target MOR mRNA antagonized NF-κB activation. These data suggest that activation of MOR enhances neuroinflammation and degeneration.

In this study, we examined the interaction of MOR antagonist naltrexone after injury in cultured cells and an animal model of TBI. We demonstrated that naltrexone significantly mitigated microglia activation in neuron/microglia co-culture and reduced IBA1 and iNOS expression, as well as behavior deficits, in the TBI mice. Similar protective responses have been reported. Naltrexone attenuated the expression of BAD and BAX in mouse brain. These data suggest that naltrexone is neuroprotective against TBI-mediated neuroinflammation and neurodegeneration.

TBI can lead to chronic neurodegeneration and long-term neurological deficits. For example, neurological severity scores, rotarod latency, impairments of cognitive function in Y or Water maze, foot faults in motor function test, and forelimb asymmetry were increased and lasted up to 28-35 days after CCI in mice. A few compounds have been reported to mitigate these secondary injuries. Similar responses have also been reported in other brain injuries. Neuronal loss and neuroinflammation were found at weeks after stroke in rats. (+)-Naloxone antagonized the delayed microglia/macrophage activation and behavioral deficits in chronic stroke rats. In this study, we demonstrated that naltrexone reduced inflammation and improved locomotor behavior at 5 days after TBI. Naltrexone may also reduce the delayed neurodegeneration in the TBI brain, which warrants further investigation.

The role of endogenous opioids in TBI was characterized in the MOR knockout mice. These animals did not express MORs, as confirmed by qRT-PCR (Figure 7); the Kd and Bmax for kappa or delta opioid receptors were not affected. We found that TBI induced a similar upregulation of IBA1 and iNOS in the lesioned cortex, as well as behavioral deficits, in the MOR WT and KO mice receiving vehicle. Similar neurodegenerative/inflammatory change was found in WT and KO neuron/microglia co-cultures after challenging with glutamate. These data suggest that knocking out MOR did not alter endogenous protection against TBI-mediated neurodegeneration.

We found that naltrexone equally normalized behavioral deficits, microglia activation, and iNOS expression in WT and KO mice after TBI. Naltrexone also antagonized glutamate-mediated MAP2 and IBA1 expression in WT and KO neuron/microglia cultures. These data suggest that MOR is not essential for naltrexone-mediated protection, as no difference was found between WTs and
The non-opioid protective reaction of naltrexone or its analogs has been reported by other laboratories. (+) Naltrexone, which did not interact with MOR, reduced TLR2- and TLR4-mediated nitric oxide release from BV2 microglia. Intranasal delivery of (+) naloxone reduced microglia activation and promoted behavioral recovery in stroke rats through a non-MOR mechanism. These data support the non-MOR action of naltrexone after brain injury.

Previous studies have indicated that MOR regulated lymphocyte activity in brain. Similar to previous reports, we found that TBI significantly increased the expression of lymphocyte marker CD4 in the lesioned brain. Naltrexone antagonized the upregulation of CD4 in WT, but not in the KO mice. This differential response of naltrexone in WT and KO suggests that MOR is involved in the migration of CD4+ lymphocytes to the TBI. The interaction of naltrexone and peripheral lymphocytes in TBI warrants further characterization.

GDNF is a neurotrophic factor for TBI and stroke. Ischemic brain injury upregulated the expression of GDNF and its receptor GFR-alpha-1. Administration of GDNF protein or upregulation of GDNF expression reduced brain infarction and neurological deficits in stroke rats. A few studies have suggested that opioids induce protection through GDNF. Delta opioid peptide [D-ala2,D-leu5] enkephalin (DADLE) increased GDNF expression and protected against cell death in stroke brain. We found that TBI increased the expression of GDNF in the lesioned brain. Administration of naltrexone or knocking out the MOR did not alter the expression of GDNF, suggesting that naltrexone did not induce protection through GDNF in the TBI brain.

We found that naltrexone, a drug that is commonly used for the treatment of alcohol and opioid abuse, has a protective and anti-inflammatory effect in TBI mice. Our study is supported by a clinical report that a severe TBI patient developed functional improvement after naltrexone therapy. As a high incidence of TBI is associated with substance abuse and drug abuse exacerbates TBI’s degenerative effects, naltrexone may be useful for the treatment of drug addiction and the comorbidity of TBI in drug abusers.

CONCLUSION

Our data support the notion that naltrexone reduced TBI-mediated neurodegeneration and inflammation, likely through non-MOR and MOR mechanisms.

ACKNOWLEDGEMENTS

This research was supported in part by (i) National Health Research Institutes, Taiwan (NP-106-PP-02, NP-107-PP-02), and (ii) the Ministry of Science and Technology, Taiwan (MOST 108-2320-B-400-023). The authors thank Dr. Yun Wang for his critical comments.

CONFLICT OF INTEREST

There are no competing interests.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Seong-Jin Yu https://orcid.org/0000-0001-7500-5883

FIGURE 7 Naltrexone did not alter expression of MOR or GDNF in WT or KO mice. The expression of (A1 for WT; A2 for KO) MOR and (B) GDNF in lesioned (TBI) and non-lesioned side (no TBI) cerebral cortex was examined by qRT-PCR. The expression of target genes was normalized to the reference genes (beta-actin and GAPDH average) with a modified delta-delta-Ct algorithm. TBI significantly increased the GDNF expression (TBI vs no TBI) in WT (B1) and KO (B2) mice. Treatment with naltrexone did not alter the expression of (A) MOR or (B) GDNF in WT or KO mice.
REFERENCES

1. Philippe D, Dubuquoy L, Groux H, et al. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest. 2003;111(9):1329-1338. https://pubmed.ncbi.nlm.nih.gov/12727924/

2. Taylor CA, Bell JM, Breiding MJ, Xu L. Traumatic Brain Injury-Related Emergency Department Visits, Hospitalizations, and Deaths - United States, 2007 and 2013. MMWR Surveill Summ. 2017;66(9):1-16. https://www.ncbi.nlm.nih.gov/pubmed/28301451

3. van Dijk J, Dijkman MD, Ophuis RH, de Ruiter GCW, Peul WC, Polinder S. In-hospital costs after severe traumatic brain injury: a systematic review and quality assessment. PLoS One. 2019;14(5):e0216743. https://www.ncbi.nlm.nih.gov/pubmed/31071199

4. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718-779

5. Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. J Neurol. 2012;19(1):155-162.

6. Pateliya BB, Singh N, Jaggi AS. Possible role of opioids and KATP channels in neuroprotective effect of postconditioning in mice. Biol Pharm Bull. 2008;31(9):1755-1760.

7. Hsu YY, Jong YJ, Lin YT, Tseng YT, Hsu SH, Lo YC. Nanomolar naloxone attenuates neurotoxicity induced by oxidative stress and survival motor neuron protein deficiency. Neurotox Res. 2014;25(3):262-270. https://www.ncbi.nlm.nih.gov/pubmed/23893732

8. Yang L, Islam MR, Karamyan VT, Abbruscato TJ. In vitro and in vivo efficacy of a potent opioid receptor agonist, biphain, compared to subtype-selective opioid receptor agonists for stroke treatment. Brain Res. 2015;1609:1-11. https://www.ncbi.nlm.nih.gov/pubmed/25801116

9. Das M, Mohapatra S, Mohapatra SS. New perspectives on central pathology of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest. 2003;111(9):1329-1338. https://www.ncbi.nlm.nih.gov/pubmed/12727924/

10. Bachstetter AD, Rowe RK, Kaneko M, Goulding D, Lifshitz J, Van Eldik LJ. The p38alpha MAPK regulates microglial responsiveness to diffuse traumatic brain injury. J Neuroinflammation. 2012;9:236. https://www.ncbi.nlm.nih.gov/pubmed/32058974

11. Ming X, Wang H, Zhou M, et al. Valproic acid attenuates traumatic and blood-brain barrier function. Neurotox Res. 2015;24(3):459-470. https://www.ncbi.nlm.nih.gov/pubmed/25668287

12. Gentile NT, McIntosh TK. Antagonists of excitatory amino acids and endogenous opioid peptides in the treatment of experimental central nervous system injury. Ann Emerg Med. 1993;22(6):1028-1034.

13. Gessi S, Borea PA, Bencivieni S, Fazzi D, Varani K, Merighi S. The activation of mu-opioid receptor potentiates LPS-induced analgesia and morphine lethality. Brain Res Mol Brain Res. 1998;54(2):321-326. https://www.ncbi.nlm.nih.gov/pubmed/9555078

14. Yu S-J, Wu K-J, Bae E, et al. Post-treatment with posiphen reduces endoplasmic reticulum stress and neurodegeneration in stroke brain. iScience. 2020;23(2):100866. https://www.ncbi.nlm.nih.gov/pubmed/32058974

15. Wu K-J, Yu S-J, Chiang C-W, et al. Transplantation of human placenta-derived multipotent stem cells reduces ischemic brain injury in adult rats. Cell Transplant. 2015;24(3):459-470. https://www.ncbi.nlm.nih.gov/pubmed/25668287

16. Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res. 2019;30(4):2389-2826. https://www.ncbi.nlm.nih.gov/pubmed/27427408

17. Xia Y, Pu H, Leak RK, et al. Inhibition of ferroptosis attenuates tissue damage and improves long-term outcomes after traumatic brain injury in mice. CNS Neurosci Ther. 2019;25(4):465-475. https://www.ncbi.nlm.nih.gov/pubmed/30264934

18. Kwilasz AJ, Todd LS, Duran-Malle JC, et al. Experimental autoimmune encephalomyelitis (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/
TLR4 antagonist (+)-naltrexone. Behav Brain Res. 2020;396:112896. https://www.ncbi.nlm.nih.gov/pubmed/32905811

35. Suzuki S, Miyagi T, Chuang TK, Chuang LF, Doi RH, Chuang RY. Morphine upregulates mu opioid receptors of human and monkey lymphocytes. Biochem Biophys Res Commun. 2000;279(2):621-628. https://www.ncbi.nlm.nih.gov/pubmed/11118335

36. Yang Y, Ye Y, Chen C, et al. Acute traumatic brain injury induces CD4+ and CD8+ T cell functional impairment by upregulating the expression of PD-1 via the activated sympathetic nervous system. Neuroimmunomodulation. 2019;26(1):43-57. https://www.ncbi.nlm.nih.gov/pubmed/30695785

37. Arvidsson A, Kokaia Z, Airaksinen MS, Saarma M, Lindvall O. Stroke induces widespread changes of gene expression for glial cell line-derived neurotrophic factor family receptors in the adult rat brain. Neuroscience. 2001;106(1):27-41. https://www.ncbi.nlm.nih.gov/pubmed/11564414

38. Sarabi A, Chang CF, Wang Y, Hoffer BJ, Morales M. Time course study of GFR alpha-1 expression in an animal model of stroke. Exp Neurol. 2000;170(2):283-289.

39. Wang Y, Lin SZ, Chiou AL, Williams LR, Hoffer BJ. Glial cell line-derived neurotrophic factor protects against ischemia-induced injury in the cerebral cortex. J Neurosci. 1997;17(11):4341-4348. https://www.ncbi.nlm.nih.gov/pubmed/9151750

40. Harvey BK, Chen GJ, Schoen CJ, et al. An immortalized rat ventral mesencephalic cell line, RTC4, is protective in a rodent model of stroke. Cell Transplant. 2007;16(5):483-491. https://www.ncbi.nlm.nih.gov/pubmed/17708338

41. Borlongan CV, Hayashi T, Oeltgen PR, Su TP, Wang Y. Hibernation-like state induced by an opioid peptide protects against experimental stroke. BMC Biol. 2009;7:31. https://www.ncbi.nlm.nih.gov/pubmed/19534760

42. Calvanio R, Burke DT, Kim HJ, et al. Naltrexone: effects on motor function, speech, and activities of daily living in a patient with traumatic brain injury. Brain Inj. 2000;14(10):933-942. https://www.ncbi.nlm.nih.gov/pubmed/11076138

43. Barnfield TV, Leatham JM. Incidence and outcomes of traumatic brain injury and substance abuse in a New Zealand prison population. Brain Inj. 1998;12(6):455-466. https://www.ncbi.nlm.nih.gov/pubmed/9638323

How to cite this article: Wang Y-S, Hung T-W, Bae E-K, Wu K-J, Hsieh W, Yu S-J. Naltrexone is neuroprotective against traumatic brain injury in mu opioid receptor knockout mice. CNS Neurosci Ther. 2021;27:831-841. https://doi.org/10.1111/cns.13655